The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below.
If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener:
http://www.thestreet.com/k/qr/flat/stock-screener.html
Upgrades: BAM, BBBY, LMNR, TCAP
Downgrades: AMGN, HQCL, HRZN, MRCC, NMFC, PAR, PKOH, SHLM, SSB, TEDU, UBSI
Initiations: None
Read on to get TheStreet Quant Ratings' detailed report:
The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.
Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access
The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
TheStreet's Jim Cramer and Marc Chaikin, of Chaikin Analytics, spent an hour together at our offices talking all things markets. Listen to the whole conversation below. In the except above, they discuss Amgen and why Chaikin says to be careful of the stock.